09.26.23
PLT Health Solutions announced that it received an expanded license to market its botanical complex Alviolife, which is a blend of Boswellia serrata gum resin and Aegle marmelos drief fruit, better known as Indian bael, with respiratory health support claims in Canada.
A second clinical study on the ingredient, conducted in 2022, evidenced the ingredient’s efficacy in supporting lung function, aerobic exercise capacity, and overall well-being.
In Canada, the complete list of approved claims now includes:
“Respiratory health is top of mind these days, particularly with the compromised air quality we have seen throughout North America as a result of rampant wildfires,” he said. “The impressive anti-inflammatory effects of AlvioLife are responsible for its effectiveness in supporting respiratory health. Health Canada has a high bar for respiratory and clinically supported health claims, and we are proud of the quality of science supporting this innovative and impactful ingredient.”
Study Details
In the 2022 double-blind, placebo-controlled clinical study, healthy subjects who reported air pollution sensitivity took either 200 mg of the ingredient daily for six weeks or a matching placebo.
Subjects taking AlvioLife experienced statistically significant improvements from baseline and compared to placebo for lung function, lung capacity and aerobic exercise capacity. In addition to these results, the study showed reductions in reported upper respiratory tract symptoms, according to Wisconsin Upper Respiratory Symptom Scale, and improved psychological well-being.
Positive changes in immune (CD4+) and inflammatory (IL-8) biomarkers were also shown. This is the second clinical study of AlvioLife to demonstrate support for healthy respiratory activity and perceived well-being. The research was presented at the 2023 American Society of Nutrition meeting in Boston in July, and the abstract was published in the peer-reviewed journal Current Developments in Nutrition in August 2023.
A second clinical study on the ingredient, conducted in 2022, evidenced the ingredient’s efficacy in supporting lung function, aerobic exercise capacity, and overall well-being.
In Canada, the complete list of approved claims now includes:
- AlvioLife helps to support lower respiratory tract health
- AlvioLife helps to support lower respiratory tract health that includes the bronchial tubes and the lungs’ health
- Supports lower respiratory system function
- Clinically shown to support health lower respiratory system function
“Respiratory health is top of mind these days, particularly with the compromised air quality we have seen throughout North America as a result of rampant wildfires,” he said. “The impressive anti-inflammatory effects of AlvioLife are responsible for its effectiveness in supporting respiratory health. Health Canada has a high bar for respiratory and clinically supported health claims, and we are proud of the quality of science supporting this innovative and impactful ingredient.”
Study Details
In the 2022 double-blind, placebo-controlled clinical study, healthy subjects who reported air pollution sensitivity took either 200 mg of the ingredient daily for six weeks or a matching placebo.
Subjects taking AlvioLife experienced statistically significant improvements from baseline and compared to placebo for lung function, lung capacity and aerobic exercise capacity. In addition to these results, the study showed reductions in reported upper respiratory tract symptoms, according to Wisconsin Upper Respiratory Symptom Scale, and improved psychological well-being.
Positive changes in immune (CD4+) and inflammatory (IL-8) biomarkers were also shown. This is the second clinical study of AlvioLife to demonstrate support for healthy respiratory activity and perceived well-being. The research was presented at the 2023 American Society of Nutrition meeting in Boston in July, and the abstract was published in the peer-reviewed journal Current Developments in Nutrition in August 2023.
